MAZE vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Mar 18, 2026

MAZE

64.3
AI Score
VS
MAZE Wins

MRNA

63.0
AI Score

Investment Advisor Scores

MAZE

Mar 18, 2026
64score
Recommendation
BUY

MRNA

Mar 18, 2026
63score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric MAZE MRNA Winner
Forward P/E 8.5324 23.0415 MAZE
PEG Ratio 0 0 Tie
Revenue Growth 0.0% -29.8% MAZE
Earnings Growth 0.0% -85.1% MAZE
Tradestie Score 64.3/100 63.0/100 MAZE
Profit Margin 0.0% -145.2% MAZE
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation BUY BUY Tie

Frequently Asked Questions

Based on our detailed analysis, MAZE is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.